A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of locally advanced unresectable NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemotherapy or metastatic NSCLC (squamous or non squamous) * No prior systemic therapy for their locally advanced or metastatic NSCLC * Provides a fresh tumor tissue sample or archival sample collected within 2 years prior to screening * PD-L1-high (TC/TPS \>= 50%) tumor * Measurable disease based on RECIST 1.1, as determined by the investigator * Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 * Adequate Baseline organ function * Female participants of childbearing potential must use adequate contraception Exclusion Criteria: * Has NSCLC with a tumor that harbors any of the following molecular alterations: EGFR and /or ALK translocations mutations that are sensitive to available targeted inhibitor therapy, Any other known genomic aberrations or oncogenic driver mutations for which a locally approved targeted therapy is available for first-line treatment of locally advanced or metastatic NSCLC. * Had major surgery within 4 weeks or lung radiation of \>30 Gy therapy within 6 months prior to the first dose of study intervention * Received prior therapy with any immune checkpoint inhibitors * Never smoked, defined as smoking \<100 tobacco cigarettes in a lifetime * Has an invasive malignancy or history of invasive malignancy other than the disease under study within the last 5 years (clinical exceptions apply as per protocol) * Symptomatic, untreated, or actively progressing, brain metastases or any leptomeningeal disease (regardless of symptomatology, treatment status, or stability) * Autoimmune disease or syndrome that required systemic treatment within the past 2 years * Receiving systemic steroid therapy \<= 3 days prior to first dose of study intervention or any form of immunosuppressive medication * Received any live vaccine \<= 30 days prior to first dose of study intervention * Any history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis * History or evidence of cardiac abnormalities * Current unstable liver or biliary disease * Severe infection within 4 weeks prior to the first dose of study intervention * Positive for tuberculosis, human immunodeficiency virus (HIV) infection, hepatitis B surface antigen, or hepatitis C * Has advanced, symptomatic, or visceral spread and is considered to be at imminent risk of life-threatening complications (including, but not limited to, massive uncontrolled effusions \[e.g., pleural, pericardial, peritoneal\]) * Is currently participating in or has participated in a study of an investigational therapy within 4 weeks prior to the first dose of study intervention * Has a history of allogeneic tissue/stem cell transplant or solid organ transplant